0001628280-26-021504
SEC filingDBV Technologies S.A. (DBVT) reported a net loss of $146.9 million for FY 2025, up 29% from $113.9 million in 2024, driven by higher R&D expenses of $116.7 million (31% YoY increase) due to clinical trial activities and pre-commercial inventory build-up. Operating income from research tax credits rose 36% to $5.6 million, while total operating expenses increased 26% to $152.7 million. Loss from operations widened to $147.1 million from $116.6 million. Cash and cash equivalents grew to $194.2 million from $32.5 million, bolstered by $276.2 million in net financing proceeds from PIPE and ATM offerings. Balance sheet shows total assets of $233.7 million, liabilities $64.9 million, and shareholders' equity $140.2 million. Net cash used in operations was $121.2 million, up 16% YoY. Management states sufficient liquidity into Q2 2027, supporting BLA submission for Viaskin Peanut in H1 2026 and potential commercialization, assuming FDA approval.
DBV Technologies reported FY 2025 net loss of $146.9 million, a 29% increase from $113.9 million in 2024, primarily due to elevated R&D spending. Operating income from research tax credits grew 36% to $5.6 million. Total operating expenses rose 26% to $152.7 million, with R&D at $116.7 million (up 31%), sales/marketing $3.2 million (up 21%), and G&A $32.8 million (up 14%). Loss from operations expanded to $147.1 million from $116.6 million. Basic/diluted EPS was -$1.00 vs -$1.17 prior year. Cash position strengthened to $194.2 million from $32.5 million, supported by $276.2 million financing inflows. Total assets $233.7 million, liabilities $64.9 million, equity $140.2 million.
No revenue from product sales in 2025 or 2024. Operating income solely from French Research Tax Credit (CIR), increasing 36% to $5.6 million from $4.2 million, reflecting higher eligible R&D activities. Company remains pre-commercial, focused on Viaskin Peanut development.
No gross profit or margins applicable due to lack of revenue. Operating loss margin effectively -2,610% on $5.6M operating income vs $152.7M expenses. R&D dominated expenses at 76% of total operating costs, up from prior year due to clinical trials (COMFORT Toddlers initiation) and $16.1M pre-commercial inventory write-down. Employee costs rose with headcount growth in regulatory, quality, and medical affairs for BLA preparation.
Net cash used in operations $121.2 million (up 16% YoY), driven by higher R&D and personnel costs. Investing outflow $1.4 million. Financing inflow $276.2 million from PIPE ($125.5M initial + $100.7M warrant exercises) and $65M ATM sales. Net cash increase $161.7 million. Balance sheet: current assets $212.9M (cash $194.2M), non-current $20.8M, total $233.7M. Current liabilities $58.0M, non-current $6.9M. Equity $140.2M with accumulated deficit -$393.1M offset by $377.5M additional paid-in capital.
Management affirms sufficient liquidity into Q2 2027 excluding non-Viaskin Peanut programs. BLA submission for Viaskin Peanut (4-7 year-olds) on track for H1 2026 post-VITESSE success. COMFORT Toddlers ongoing for 1-3 year-olds under Accelerated Approval pathway. $85M remaining ATM capacity plus warrants provide flexibility. Material commitments total $147M (CRO $89.8M, CMO $48.7M, leases $8.4M). Risks include regulatory delays, commercialization costs, and need for additional financing.